Headquartered in Carlsbad, CA·Fiscal year ends December·NASDAQ: ATEC·atecspine.com
About Alphatec
Alphatec Holdings, Inc. (ATEC) is a medical device company focused exclusively on spine surgery. It operates through its wholly owned subsidiaries Alphatec Spine, Inc., EOS imaging S.A.S., and SafeOp Surgical, Inc.
The company sells procedural solutions for spine surgery, including surgical hardware (implants and instruments) and biologics, which together make up its Surgical revenue. Through EOS it also offers imaging systems. Its Organic Innovation Machine develops new surgical approaches designed to integrate with the expanding InformatiX platform, which aims to better inform surgery and make spine procedures safer and more reproducible.
ATEC's strategy centers on driving surgeon adoption and procedural volume. It also aims to improve the share of revenue each procedure generates by attaching biologics, and it is pursuing a longer-term biologics opportunity with OsteoAdapt (Theradaptive). In Q3 2026, surgical revenue was about $202 million of the roughly $221 million total. The company has moved to positive GAAP operating income and expanding adjusted EBITDA margins, though it still carries significant convertible and long-term debt. Updated
Pre-Market Stock Futures: Futures are trading lower after a big rate-cut rally on Wednesday was sideswiped by Oracle’s disappointing earnings after the bell yesterday. The Federal Reserve’s 25-basis-point rate cut, as expected,…
Alphatec Holdings, Inc. (ATEC) is a medical device company focused exclusively on spine surgery. It operates through its wholly owned subsidiaries Alphatec Spine, Inc., EOS imaging S.A.S., and SafeOp Surgical, Inc.
What is the ATEC stock price target?
The Wall Street consensus 12-month price target for ATEC is $12.93.